Board of directors and committ

Board of Directors
Board members have a wide range of expertise, skills, and literacy in terms of the company's operations and development needs. They have expertise in finance, accounting, marketing, business and industry, and can provide professional advice and advice. At present, the board of directors consists of 6 directors and 3 independent directors. The board of directors is held at least once a quarter. In addition, the company also has rules and regulations such as the election rules for directors and supervisors, the rules for directors' meetings, and the rules for the scope of duties of independent directors.
Position NameGender
Major academic and
career achievements
Other position
Center Laboratories Inc.
Jung-Chin Lin
Honorary Doctorate, Taipei Medical University
Bachelor, School of Pharmacy, Taipei Medical University
Chairman (Legal Representative),Center Laboratories Inc.
Legal Representative Director/President/CEO, Lumosa
Therapeutics Co. Ltd.
Legal Representative Director, Adimmue Corporation
Legal Representative Director, BioGend Therapeutics Co., Ltd.
Bioflag International Corporation
Chairman (Legal Representative), GLAC Biotech Co., Ltd.
Chairman (Legal Representative), BioEngine Capital Inc.
Chairman (Legal Representative), BioEngine Technology
Development Inc.
Chairman (Legal Representative), BRIM Biotechnology, Inc.
Chairman, Royal Foods Co., Ltd.
Chairman (Legal Representative), Ausnutria Dairy (Taiwan)
Nutrition & Health Sciences Corporation
Chairman (Legal Representative), Youluck International Inc.
Director, A2+ Biotech Consulting Co., Ltd.
Director, Beijing Shundu Pharmaceutical Research Institute Co., Ltd.
Legal Representative Director, Bioflag International Corporation
Chairman, O'Long Enterprises Ltd. (BVI)
Chairman, Centerlab Investment Holding Limited (HK)
Chairman, Centerlab Investment Holding Limited (HK)
Chairman, BioEngine Capital Holding Limited (HK)
Chairman, BioEngine Investment Holding Limited (HK)
Center Laboratories Inc.
Chun-Hong Chen
MaleBA, Business Administration, Union
University of Business
Chairman (Legal Representative), MasterLink Securities
Legal Representative Director, Center Laboratories Inc.
Legal Representative Director, BioEngine Capital Inc.
Legal Representative Supervisor, Hi-Clearance Inc.
Legal Representative Director, BioEngine Technology
Development Inc.
DirectorNien Hsing Interbational Investment Co., Ltd.
En-Tzn Liu
FemaleAssistant manager, Deloitte Touche Tohmatsu Limited
Master of Accounting , National Taiwan University
Legal Representative Director, BioGend Therapeutics Co., Ltd
Financial Manager and Corporate Governance Manager, Nien Hsing Textile Co., Ltd.
DirectorJason Technology Co., Ltd.
Chia-Ling Lin
MaleBachelor, Department
of Economics,
McMaster University
Director (Legal Representative), Center Laboratories Inc.
Director (Legal Representative), BioEngine Capital Inc.
Director (Legal Representative),, BioEngine Technology
Development Inc./ Investment Manager
Supervisor, LeJean Biotech Co., Ltd.
Supervisor, Jason Technology Co., Ltd.
Supervisor, Royal Foods Co., Ltd.
DirectorYong Lien Corp.
Wann-Lai Cheng
Bachelor, Business Administration, Fu-Jen
Catholic University

Chairman, Taiwan Calsonic Co., Ltd.
Chairman, Yong Lien Corp.
Chairman, Browave Corp.
Independent Director, Powertech Technology Inc.
Director, Center Laboratories Inc.
Director (Legal Representative), Lumosa Therapeutics Co., Ltd
Director (Legal Representative), GLAC BIOTECH Co., Ltd
Director (Legal Representative), BioEngine Capital Inc.
Director (Legal Representative), BioEngine Technology
Development Inc.
DirectorChina Investment
and Development
Co., LTD.
Hsiu-Yuan Lee
FemaleMaster of Economics, San Jose State University, USADirector (Legal Representative), China Investment
and Development Co., LTD.
Director (Legal Representative) and President, CIDC Consultants INC.
Director (Legal Representative), Maxigen Biotech Inc.
Director (Legal Representative), InnoPharmax Inc.
Director (Legal Representative), Intech Biopharm Ltd.
Director (Legal Representative), Advagene Biopharma Co., Ltd.
Director (Legal Representative), Acepodia Biotechnologies, Limited
Director, Acepodoa, Inc.
Kuo-Pin KaoMaleBachelor, Department of economics, National Chung Hsing UniversityChairman, P&L Investment Corp.
M. Sherry KuFemalePh.D.of Pharmaceutics and Pharmacology, The Ohio State University
President, TWi Pharmaceuticals, Inc.
Head of Early pharmaceutical Development, Wyeth Research USA
Chairmen & Chief Executive Officer
Savior Lifetec Corp. (SLC)
Director, National Synchrotron Radiation Research Center
Yu-Sheng TsaiMaleBachelor, National Chung Hsing University(Now National Taipei University)
Master of Law,  Fu Jen Catholic University
EMBA, National Chengchi University
Pass of the Bar Examination
Lawyer of Legal Aid Foundation
Arbitrator of Chinese Arbitration Association, Taipei
Lawyer of honor,
Small and Medium Enterprise Administration, Ministry of Economic Affairs
Managing Attorney, Genda Law Firm
Independent Director, Lian Fa International Dinng Business Corp.
Supervisor, WebComm Technology Co. , Ltd. 

Audit Committee
The audit committee shall be composed of the entire number of independent directors. It shall not be fewer than three persons in number, one of whom shall be convener, and at least one of whom shall have accounting or financial expertise.
The independent director members of the Committee shall serve a 3-year term, and may be re-elected to further terms. When the number of the independent director members on the Committee falls below that prescribed in the preceding paragraph or in the articles of incorporation due to an independent director's dismissal for any reason, a by-election shall be held at the next shareholders meeting to fill the vacancy. When the independent directors are dismissed en masse, a special shareholders meeting shall be called within 60 days from the date of the occurrence to hold a by-election to fill the vacancies.
The powers of the Committee are as follows:
1.The adoption of or amendments to the internal control system pursuant to Article 14-1 of the Securities and Exchange Act.
2.Assessment of the effectiveness of the internal control system.
3.The adoption or amendment, pursuant to Article 36-1 of the Securities and Exchange Act, of the procedures for handling financial or business activities of a material nature, such as acquisition or disposal of assets, derivatives trading, loaning of funds to others, and endorsements or guarantees for others.
4.Matters in which a director is an interested party.
5.Asset transactions or derivatives trading of a material nature.
6.Loans of funds, endorsements, or provision of guarantees of a material nature.
7.The offering, issuance, or private placement of equity-type securities.
8.The hiring or dismissal of a certified public accountant, or their compensation.
9.The appointment or discharge of a financial, accounting, or internal audit officer.
10.Annual and semi-annual financial reports.
11.Other material matters as may be required by this Corporation or by the competent authority.
Position Name
ConvenerKuo-Pin Kao
Member M. Sherry Ku
Member Yu-Sheng Tsai

Remuneration Committee
The Committee shall not be fewer than three persons in members appointed by resolution of the board of directors.
The company has established independent directors in accordance with the provisions of the Securities and Exchange Law. More than half of the members of this committee shall be independent directors, and all members shall elect independent directors to serve as the convener.
Position Name
ConvenerKuo-Pin Kao
Member M. Sherry Ku
Member Yu-Sheng Tsai